NuVasive Stock Price, News & Analysis (NASDAQ:NUVA)

$51.39 +0.56 (+1.10 %)
(As of 03/21/2018 12:48 PM ET)
Previous Close$50.83
Today's Range$50.67 - $51.42
52-Week Range$44.62 - $81.68
Volume79,019 shs
Average Volume954,154 shs
Market Capitalization$2.61 billion
P/E Ratio33.01
Dividend YieldN/A

About NuVasive (NASDAQ:NUVA)

NuVasive logoNuVasive, Inc., a medical device company, develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal product is Maximum Access Surgery, a minimally-disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics. Its spine surgery product line offerings comprise products for the thoracolumbar and the cervical spine, which are primarily used to enable surgeons to access the spine and to perform restorative and fusion procedures in a minimally-disruptive fashion. Its biologics products include Osteocel Plus and Pro, a cellular bone matrix; Formagraft, a collagen-based synthetic bone substitute; AttraX, a synthetic bone graft material; and Propel DBM, a moldable demineralized bone matrix putty, which are used for spinal fusion or bone healing process. The company's IOM services are used for onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. It also provides implants used for interbody disc height restoration; and fixation products, including pedicle screws, rods, and plates. In addition, the company offers Integrated Global Alignment platform for assessing, preserving, and restoring spinal alignment; MAGEC-early onset scoliosis, a spinal bracing and distraction system; and PRECICE, a limb lengthening system. NuVasive, Inc. sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly-employed sales personnel, and distributors in the United States and internationally. The company was founded in 1997 and is headquartered in San Diego, California.

Receive NUVA News and Ratings via Email

Sign-up to receive the latest news and ratings for NUVA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry MED PRODS
Sub-IndustryHealth Care Equipment


Debt-to-Equity Ratio0.73%
Current Ratio3.48%
Quick Ratio1.94%


Trailing P/E Ratio33.0064935064935
Forward P/E Ratio20.89
P/E Growth1.3

Sales & Book Value

Annual Sales$1.03 billion
Price / Sales2.56
Cash Flow$4.79 per share
Price / Cash10.73
Book Value$15.68 per share
Price / Book3.28


Trailing EPS$1.54
Net Income$83 million
Net Margins8.06%
Return on Equity13.40%
Return on Assets6.20%


Outstanding Shares51,260,000

NuVasive (NASDAQ:NUVA) Frequently Asked Questions

What is NuVasive's stock symbol?

NuVasive trades on the NASDAQ under the ticker symbol "NUVA."

How will NuVasive's stock buyback program work?

NuVasive announced that its board has authorized a share buyback plan on Wednesday, October 25th 2017, which permits the company to buyback $100,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to repurchase shares of its stock through open market purchases. Shares buyback plans are generally an indication that the company's management believes its shares are undervalued.

How were NuVasive's earnings last quarter?

NuVasive, Inc. (NASDAQ:NUVA) issued its quarterly earnings data on Monday, February, 26th. The medical device company reported $0.56 EPS for the quarter, hitting analysts' consensus estimates of $0.56. The medical device company had revenue of $271.70 million for the quarter, compared to analyst estimates of $272.11 million. NuVasive had a return on equity of 13.40% and a net margin of 8.06%. NuVasive's quarterly revenue was up .2% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.53 earnings per share. View NuVasive's Earnings History.

When will NuVasive make its next earnings announcement?

NuVasive is scheduled to release their next quarterly earnings announcement on Monday, April, 23rd 2018. View Earnings Estimates for NuVasive.

What guidance has NuVasive issued on next quarter's earnings?

NuVasive issued an update on its FY18 earnings guidance on Monday, February, 26th. The company provided earnings per share guidance of $2.44-2.47 for the period, compared to the Thomson Reuters consensus estimate of $2.34. The company issued revenue guidance of $1.095-1.105 billion, compared to the consensus revenue estimate of $1.09 billion.

Where is NuVasive's stock going? Where will NuVasive's stock price be in 2018?

15 brokers have issued twelve-month target prices for NuVasive's stock. Their forecasts range from $52.00 to $90.00. On average, they expect NuVasive's share price to reach $68.21 in the next twelve months. View Analyst Ratings for NuVasive.

What are Wall Street analysts saying about NuVasive stock?

Here are some recent quotes from research analysts about NuVasive stock:

  • 1. According to Zacks Investment Research, "NuVasive's recent quarterly performances were promising significantly driven by solid international growth. The last-reported third quarter marked the fourth consecutive one registering more than 20% growth in international business. However, overall sales in the quarter were impacted by procedural volume-related challenges in the United States and the adverse impact of hurricanes Harvey and Irma on NuVasive’s U.S. results and Maria on the international front. With chances of fourth-quarter revenues being affected by Maria in Puerto Rico and with the anticipated lower U.S. procedural volumes to continue, NuVasive is pressed to reduce its full-year guidance, which is disappointing. Also, the contraction in gross margin is a matter of concern. Overall, for the past six months, NuVasive has been trading below the broader industry." (2/20/2018)
  • 2. Needham & Company LLC analysts commented, "We are upgrading NUVA to Buy from Underperform since: 1) we believe that consensus revenue and EPS estimates have declined to levels that are more realistic and likely conservative, 2) NUVA has done several acquisitions that probably aren’t fully factored into consensus revenue or EPS estimates (Vertera and SafePassage, which we estimate could add ~2% to NUVA’s 2018 revenue), 3) NUVA should see a significant benefit from tax reform (which we expect to increase its EPS by ~15% in 2018), and 4) we think NUVA shares are attractively valued considering the expected benefit from tax reform. We have raised our revenue and EPS estimates to reflect recent deals and tax reform." (1/4/2018)
  • 3. Canaccord Genuity analysts commented, "We note leading indicators of forward growth — new product flow (Less-ray, cervical iGA, Unite, pediatric deformity, expandable cages) and sales rep additions (+15 percent Y/Y in 2016) — should drive incremental growth opportunities entering the H2/16," the analyst said.On Track to Deliver Meaningful LeverageCanaccord Genuity believes the company is on track to deliver meaningful leverage over the next five years, although it expects M&A and continued investments to offset near-term improvements in operating margins."In sum, we continue to view the margin story positively but expect 2017 to be back-end loaded as NUVA realizes the benefits of sales force investments (building out peds team) and marketing efforts in Japan," the firm said.Guidance Reflects Changing SeasonalityThe firm noted that the company guided full-year revenues to $1.065 million, including a $10 million forex headwind, adjusted operating margins of 17.1 percent, up 100 basis points year-over-year, and earnings of $2 per share. However, the second quarter revenue guidance of $262 million was about $5 million below the consensus estimate, the firm added.According to the firm, this reflects the changing seasonality of the revenue cadence post the Ellipse Biotronic acquisitions. Concluding, the firm said, "We continue to believe that NuVasive is in prime share-taking position in the global spine market, driven by innovative new product flow, robust sales force additions, and broader tailwinds such as vendor consolidation."Furthermore, the margin expansion story remains intact and we see upside bias to estimates despite the second-half weighted guidance." (4/26/2017)

Who are some of NuVasive's key competitors?

Who are NuVasive's key executives?

NuVasive's management team includes the folowing people:

  • Mr. Gregory T. Lucier, Chairman & CEO (Age 54)
  • Mr. Matthew W. Link, Exec. VP of Strategy, Technology & Corp. Devel. (Age 43)
  • Mr. Jason Marshall Hannon, Former Pres & COO (Age 46)
  • Mr. Rajesh J. Asarpota, Exec. VP & CFO (Age 51)
  • Mr. Jereme Sylvain, Chief Accounting Officer (Age 38)

Has NuVasive been receiving favorable news coverage?

Media stories about NUVA stock have been trending somewhat positive this week, Accern reports. The research group ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. NuVasive earned a news sentiment score of 0.10 on Accern's scale. They also assigned news stories about the medical device company an impact score of 52.01 out of 100, indicating that recent media coverage is somewhat likely to have an impact on the company's share price in the next several days.

Who are NuVasive's major shareholders?

NuVasive's stock is owned by many different of retail and institutional investors. Top institutional investors include Champlain Investment Partners LLC (5.62%), Viking Global Investors LP (3.51%), Fisher Asset Management LLC (2.53%), Eagle Asset Management Inc. (2.23%), OppenheimerFunds Inc. (2.07%) and TIAA CREF Investment Management LLC (1.65%). Company insiders that own NuVasive stock include Gregory T Lucier, Jason Hannon, Joan Stafslien, Lesley H Howe, Matthew Link, Michael D Ohalleran, Patrick Miles and Peter Michael Leddy. View Institutional Ownership Trends for NuVasive.

Which major investors are selling NuVasive stock?

NUVA stock was sold by a variety of institutional investors in the last quarter, including Viking Global Investors LP, TIAA CREF Investment Management LLC, Guggenheim Capital LLC, OppenheimerFunds Inc., Teachers Advisors LLC, Metropolitan Life Insurance Co. NY, Tekla Capital Management LLC and Engineers Gate Manager LP. View Insider Buying and Selling for NuVasive.

Which major investors are buying NuVasive stock?

NUVA stock was bought by a variety of institutional investors in the last quarter, including Carillon Tower Advisers Inc., Consonance Capital Management LP, State of Tennessee Treasury Department, AXA, Macquarie Group Ltd., Victory Capital Management Inc., Rice Hall James & Associates LLC and Champlain Investment Partners LLC. Company insiders that have bought NuVasive stock in the last two years include Gregory T Lucier, Joan Stafslien, Michael D Ohalleran, Patrick Miles and Peter Michael Leddy. View Insider Buying and Selling for NuVasive.

How do I buy shares of NuVasive?

Shares of NUVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is NuVasive's stock price today?

One share of NUVA stock can currently be purchased for approximately $51.39.

How big of a company is NuVasive?

NuVasive has a market capitalization of $2.61 billion and generates $1.03 billion in revenue each year. The medical device company earns $83 million in net income (profit) each year or $1.54 on an earnings per share basis. NuVasive employs 2,600 workers across the globe.

How can I contact NuVasive?

NuVasive's mailing address is 7475 LUSK BOULEVARD, SAN DIEGO CA, 92121. The medical device company can be reached via phone at 858-909-1800 or via email at [email protected]

MarketBeat Community Rating for NuVasive (NUVA)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  560 (Vote Outperform)
Underperform Votes:  445 (Vote Underperform)
Total Votes:  1,005
MarketBeat's community ratings are surveys of what our community members think about NuVasive and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

NuVasive (NASDAQ:NUVA) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.732.732.732.71
Ratings Breakdown: 0 Sell Rating(s)
4 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
2 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
2 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $68.21$71.64$71.69$79.75
Price Target Upside: 32.74% upside46.60% upside21.18% upside46.04% upside

NuVasive (NASDAQ:NUVA) Consensus Price Target History

Price Target History for NuVasive (NASDAQ:NUVA)

NuVasive (NASDAQ:NUVA) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/27/2018Robert W. BairdReiterated RatingHold$55.00LowView Rating Details
2/27/2018CowenSet Price TargetBuy$62.00LowView Rating Details
2/27/2018BarclaysReiterated RatingOverweight -> Buy$66.00 -> $62.00LowView Rating Details
2/27/2018Morgan StanleyReiterated RatingEqual Weight -> Equal Weight$67.00 -> $55.00HighView Rating Details
2/27/2018Leerink SwannBoost Price TargetMarket Perform -> Market Perform$51.00 -> $52.00LowView Rating Details
2/27/2018Canaccord GenuityLower Price TargetBuy -> Buy$81.00 -> $73.00LowView Rating Details
2/27/2018Needham & Company LLCReiterated RatingBuy -> Buy$71.00 -> $70.00LowView Rating Details
1/17/2018Wells FargoDowngradeOutperform -> Market Perform$65.00MediumView Rating Details
1/9/2018Piper Jaffray CompaniesReiterated RatingBuy$90.00HighView Rating Details
12/14/2017BMO Capital MarketsReiterated RatingBuy$70.00MediumView Rating Details
12/13/2017BTIG ResearchSet Price TargetBuy$74.00LowView Rating Details
11/10/2017Royal Bank of CanadaLower Price TargetOutperform -> Outperform$75.00 -> $70.00N/AView Rating Details
10/25/2017JPMorgan Chase & Co.Set Price TargetBuy$78.00N/AView Rating Details
10/3/2017Jefferies GroupReiterated RatingBuy$79.00LowView Rating Details
9/21/2017GabelliReiterated RatingBuyLowView Rating Details
11/30/2016AegisInitiated CoverageBuy$72.00N/AView Rating Details
7/27/2016Brean CapitalBoost Price TargetBuy$60.00 -> $70.00N/AView Rating Details
(Data available from 3/21/2016 forward)


NuVasive (NASDAQ:NUVA) Earnings History and Estimates Chart

Earnings by Quarter for NuVasive (NASDAQ:NUVA)

NuVasive (NASDAQ NUVA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/23/2018$0.45N/AView Earnings Details
2/26/2018Q4 2017$0.56$0.56$272.11 million$271.70 millionViewListenView Earnings Details
10/24/2017Q3 2017$0.48$0.52$255.70 million$247.40 millionViewN/AView Earnings Details
7/27/2017Q2 2017$0.44$0.46$261.95 million$260.60 millionViewN/AView Earnings Details
4/25/2017Q1 2017$0.37$0.38$250.52 million$249.86 millionViewN/AView Earnings Details
2/9/2017Q416$0.51$0.53$261.25 million$271.10 millionViewListenView Earnings Details
10/25/2016Q316$0.40$0.40$243.49 million$239.60 millionViewListenView Earnings Details
7/26/2016Q216$0.36$0.40$232.86 million$236.50 millionViewListenView Earnings Details
4/26/2016Q116$0.27$0.31$205.54 million$215.10 millionViewListenView Earnings Details
2/11/2016Q415$0.31$0.35$215.08 million$215.30 millionViewListenView Earnings Details
10/27/2015Q315$0.27$0.35$200.21 million$200.50 millionViewListenView Earnings Details
7/28/2015Q215$0.25$0.31$200.71 million$202.91 millionViewListenView Earnings Details
5/4/2015Q115$0.21$0.30$189.30 million$192.40 millionViewListenView Earnings Details
2/24/2015Q4$0.37$0.39$201.40 million$204.30 millionViewListenView Earnings Details
10/30/2014Q314$0.14$0.09$179.30 million$189.90 millionViewListenView Earnings Details
7/29/2014Q214$0.25$0.28$177.50 million$190.70 millionViewListenView Earnings Details
4/29/2014Q114$0.13$0.29$171.30 million$177.50 millionViewListenView Earnings Details
3/3/2014Q413$0.32$0.37$181.24 million$190.80 millionViewListenView Earnings Details
10/29/2013Q313$0.24$0.39$158.30 million$169.20 millionViewListenView Earnings Details
7/30/2013Q2 2013$0.23$0.20$161.67 million$165.70 millionViewListenView Earnings Details
4/30/2013Q1 2013$0.22$0.26$157.34 million$159.50 millionViewListenView Earnings Details
2/26/2013Q4 2012$0.21$0.34$156.35 million$165.80 millionViewListenView Earnings Details
10/24/2012$0.21$0.23ViewN/AView Earnings Details
7/25/2012$0.23$0.27ViewN/AView Earnings Details
4/30/2012$0.18$0.20ViewN/AView Earnings Details
2/22/2012$0.22$0.27ViewN/AView Earnings Details
10/27/2011$0.24$0.26ViewN/AView Earnings Details
7/25/2011$0.28$0.30ViewN/AView Earnings Details
5/5/2011$0.19$0.24ViewN/AView Earnings Details
2/23/2011$0.42$0.46ViewN/AView Earnings Details
10/28/2010Q3 2010$0.26$0.29ViewN/AView Earnings Details
7/27/2010Q2 2010$0.18$0.24ViewN/AView Earnings Details
4/20/2010Q1 2010$0.07$0.09ViewN/AView Earnings Details
2/25/2010Q4 2009$0.11$0.11ViewN/AView Earnings Details
10/20/2009Q3 2009$0.05$0.15ViewN/AView Earnings Details
7/23/2009Q2 2009($0.02)$0.07ViewN/AView Earnings Details
4/22/2009Q1 2009($0.20)($0.02)ViewN/AView Earnings Details
2/25/2009Q4 2008$0.12$0.16ViewN/AView Earnings Details
10/22/2008Q3 2008$0.01$0.04ViewN/AView Earnings Details
7/24/2008Q2 2008($0.03)($0.01)ViewN/AView Earnings Details
4/22/2008Q1 2008($0.10)($0.10)ViewN/AView Earnings Details
2/19/2008Q4 2007($0.04)($0.03)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


NuVasive (NASDAQ:NUVA) Earnings Estimates

2018 EPS Consensus Estimate: $2.46
2019 EPS Consensus Estimate: $2.59
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183$0.44$0.49$0.46
Q2 20183$0.58$0.62$0.60
Q3 20183$0.61$0.67$0.63
Q4 20183$0.74$0.82$0.77
Q1 20191$0.55$0.55$0.55
Q2 20191$0.65$0.65$0.65
Q3 20191$0.64$0.64$0.64
Q4 20191$0.75$0.75$0.75
(Earnings estimates data provided by Zacks Investment Research)


Dividend History for NuVasive (NASDAQ:NUVA)

No dividend announcements for this company have been tracked by

Insider Trades

NuVasive (NASDAQ NUVA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.20%
Insider Trades by Quarter for NuVasive (NASDAQ:NUVA)
Institutional Ownership by Quarter for NuVasive (NASDAQ:NUVA)

NuVasive (NASDAQ NUVA) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/6/2018Gregory T LucierCEOBuy6,000$50.30$301,800.00View SEC Filing  
3/1/2018Gregory T LucierCEOBuy6,000$48.57$291,420.00View SEC Filing  
8/29/2017Gregory T LucierCEOBuy2,000$61.52$123,040.00View SEC Filing  
8/18/2017Lesley H. HoweDirectorSell3,970$64.64$256,620.80View SEC Filing  
8/17/2017Gregory T LucierCEOBuy5,000$66.22$331,100.00View SEC Filing  
8/1/2017Peter Michael LeddyEVPBuy7,850$63.88$501,458.00View SEC Filing  
3/8/2017Jason HannonInsiderSell24,840$74.22$1,843,624.80View SEC Filing  
2/14/2017Lesley H. HoweDirectorSell6,049$73.26$443,149.74View SEC Filing  
12/12/2016Matthew LinkInsiderSell10,303$67.99$700,500.97View SEC Filing  
11/4/2016Michael D OhalleranDirectorBuy4,200$58.26$244,692.00View SEC Filing  
11/2/2016Patrick MilesDirectorBuy16,967$58.97$1,000,543.99View SEC Filing  
11/1/2016Patrick MilesDirectorBuy16,667$59.00$983,353.00View SEC Filing  
10/31/2016Joan StafslienEVPBuy5,000$59.68$298,400.00View SEC Filing  
10/31/2016Michael D OhalleranDirectorBuy4,205$59.47$250,071.35View SEC Filing  
8/23/2016Jason HannonEVPSell2,625$64.80$170,100.00View SEC Filing  
8/2/2016Jason HannonEVPSell11,184$62.70$701,236.80View SEC Filing  
8/2/2016Lesley H. HoweDirectorSell3,602$62.44$224,908.88View SEC Filing  
7/20/2016Jason HannonEVPSell2,920$62.80$183,376.00View SEC Filing  
6/16/2016Jason HannonEVPSell14,534$57.57$836,722.3837,616View SEC Filing  
1/6/2016Patrick MilesCOOSell10,723$54.03$579,363.6931,646View SEC Filing  
12/16/2015Patrick MilesCOOSell9,127$52.56$479,715.1231,646View SEC Filing  
12/7/2015Quentin S BlackfordCFOSell15,000$51.10$766,500.002,599View SEC Filing  
12/3/2015Patrick MilesCOOSell5,873$52.51$308,391.2340,773View SEC Filing  
11/2/2015Patrick MilesCOOSell15,000$48.12$721,800.0032,627View SEC Filing  
10/5/2015Matthew LinkinsiderSell1,714$50.72$86,934.0853,089View SEC Filing  
10/3/2015Quentin S BlackfordCFOSell5,000$36.30$181,500.00View SEC Filing  
10/1/2015Patrick MilesCOOSell15,000$48.10$721,500.0047,627View SEC Filing  
9/8/2015Russell PowersEVPSell5,806$51.64$299,821.8462,024View SEC Filing  
9/2/2015Jason HannonEVPSell11,962$52.02$622,263.2418,565View SEC Filing  
9/1/2015Patrick MilesCOOSell15,000$52.03$780,450.0062,627View SEC Filing  
8/31/2015Patrick MilesCOOSell15,000$53.34$800,100.0062,627View SEC Filing  
7/20/2015Jason HannonEVPSell15,000$49.60$744,000.00View SEC Filing  
6/15/2015Gregory T LucierCEOBuy4,491$49.49$222,259.59View SEC Filing  
6/12/2015Gregory T LucierCEOBuy8,000$50.10$400,800.00View SEC Filing  
6/10/2015Gregory T LucierCEOBuy10,000$49.10$491,000.00View SEC Filing  
6/8/2015Gregory T LucierCEOBuy10,000$49.26$492,600.00View SEC Filing  
6/4/2015Gregory T LucierCEOBuy10,000$49.71$497,100.00View SEC Filing  
6/2/2015Gregory T LucierCEOBuy8,000$49.96$399,680.00View SEC Filing  
6/2/2015Patrick MilesCOOSell4,194$49.47$207,477.18View SEC Filing  
5/29/2015Jack R BlairDirectorSell3,703$50.16$185,742.48View SEC Filing  
5/28/2015Gregory T LucierCEOBuy34,000$49.25$1,674,500.00View SEC Filing  
5/28/2015Russell PowersEVPSell8,042$49.00$394,058.00View SEC Filing  
5/19/2015Patrick MilesCOOSell15,000$47.52$712,800.00View SEC Filing  
5/1/2015Russell PowersEVPSell11,881$45.21$537,140.01View SEC Filing  
4/24/2015Russell PowersEVPSell3,888$44.07$171,344.16View SEC Filing  
3/13/2015Patrick MilesCOOSell7,920$45.52$360,518.40View SEC Filing  
3/9/2015Alexis V LukianovCEOSell5,313$44.82$238,128.66View SEC Filing  
3/3/2015Matthew LinkInsiderSell7,500$44.46$333,450.00View SEC Filing  
3/2/2015Jason HannonEVPSell5,085$45.06$229,130.10View SEC Filing  
2/9/2015Alexis V LukianovCEOSell5,454$46.10$251,429.40View SEC Filing  
2/5/2015Matthew LinkInsiderSell4,078$45.77$186,650.06View SEC Filing  
2/3/2015Patrick MilesCOOSell15,000$45.53$682,950.00View SEC Filing  
1/28/2015Keith ValentineCOOSell6,970$46.96$327,311.20View SEC Filing  
1/12/2015Alexis V LukianovCEOSell7,452$49.69$370,289.88View SEC Filing  
1/5/2015Jason HannonEVPSell12,117$46.82$567,317.94View SEC Filing  
1/5/2015Patrick MilesInsiderSell15,000$46.61$699,150.00View SEC Filing  
12/30/2014Jason HannonEVPSell15,000$47.63$714,450.00View SEC Filing  
12/29/2014Jason HannonEVPSell3,146$47.57$149,655.22View SEC Filing  
12/24/2014Patrick MilesInsiderSell15,000$47.52$712,800.00View SEC Filing  
12/19/2014Keith ValentineCOOSell5,893$47.78$281,567.54View SEC Filing  
12/1/2014Keith ValentineCOOSell2,500$43.66$109,150.00View SEC Filing  
11/19/2014Keith ValentineCOOSell5,582$43.32$241,812.24View SEC Filing  
11/19/2014Quentin S BlackfordCFOSell7,698$43.41$334,170.18View SEC Filing  
11/7/2014Alexis V LukianovCEOSell25,000$41.40$1,035,000.00View SEC Filing  
11/3/2014Keith ValentineCOOSell2,500$40.61$101,525.00View SEC Filing  
10/2/2014Keith ValentineCOOSell2,500$35.00$87,500.00View SEC Filing  
9/2/2014Keith ValentineCOOSell2,500$35.14$87,850.00View SEC Filing  
8/1/2014Keith ValentineCOOSell2,500$37.11$92,775.00View SEC Filing  
8/1/2014Michael LambertCFOSell4,010$37.11$148,811.10View SEC Filing  
7/30/2014Jason HannonEVPSell5,000$39.00$195,000.00View SEC Filing  
7/10/2014Russell PowersEVPSell3,200$33.43$106,976.00View SEC Filing  
7/1/2014Keith ValentineCOOSell2,500$35.65$89,125.00View SEC Filing  
7/1/2014Michael LambertCFOSell23,225$35.48$824,023.00View SEC Filing  
6/20/2014Keith ValentineCOOSell5,000$35.00$175,000.00View SEC Filing  
6/20/2014Russell PowersEVPSell9,526$35.00$333,410.00View SEC Filing  
5/5/2014Robert HuntDirectorSell20,000$34.25$685,000.0034,500View SEC Filing  
5/2/2014Michael LambertCFOSell13,096$33.07$433,084.7251,695View SEC Filing  
4/1/2014Keith ValentineCOOSell2,500$38.41$96,025.0088,985View SEC Filing  
3/11/2014Peter FarrellDirectorSell48,000$36.88$1,770,240.006,794View SEC Filing  
1/21/2014Jason HannonEVPSell10,095$36.60$369,477.008,899View SEC Filing  
1/16/2014Keith ValentineCOOSell20,000$37.96$759,200.0044,226View SEC Filing  
1/7/2014Alexis LukianovCEOSell34,217$34.29$1,173,300.9355,740View SEC Filing  
1/7/2014Craig HunsakerSVPSell4,980$35.00$174,300.0021,142View SEC Filing  
12/30/2013Craig HunsakerSVPSell4,275$32.10$137,227.5024,980View SEC Filing  
12/23/2013Michael LambertCFOSell17,091$32.49$555,286.5913,096View SEC Filing  
11/7/2013Alexis LukianovCEOSell5,000$31.45$157,250.0072,827View SEC Filing  
10/30/2013Jason HannonEVPSell2,334$28.90$67,452.60View SEC Filing  
10/30/2013Patrick MilesInsiderSell21,223$31.10$660,035.30View SEC Filing  
10/28/2013Patrick MilesInsiderSell7,331$25.72$188,553.32View SEC Filing  
10/21/2013Russell PowersVPSell12,500$25.39$317,375.00View SEC Filing  
10/11/2013Jason HannonEVPSell1,000$26.00$26,000.0019,991View SEC Filing  
10/7/2013Jason HannonEVPSell8,705$23.99$208,832.9519,991View SEC Filing  
10/7/2013Michael LambertCFOSell15,442$24.04$371,225.6830,187View SEC Filing  
8/6/2013Richard Treharne IIIDirectorBuy2,000$23.26$46,520.00View SEC Filing  
7/12/2013Craig E HunsakerSVPSell2,000$27.00$54,000.00View SEC Filing  
7/8/2013Alexis V LukianovCEOSell5,000$25.74$128,700.00View SEC Filing  
7/1/2013Keith ValentineCOOSell1,698$25.00$42,450.00View SEC Filing  
5/13/2013Alexis V LukianovCEOSell7,500$22.71$170,325.00View SEC Filing  
5/8/2013Peter Michael LeddyDirectorBuy2,400$22.24$53,376.00View SEC Filing  
5/7/2013Alexis V LukianovCEOSell12,500$22.11$276,375.00View SEC Filing  
(Data available from 1/1/2013 forward)


NuVasive (NASDAQ NUVA) News Headlines

Orthopedic Device Market Gains Momentum: 3 Stocks in FocusOrthopedic Device Market Gains Momentum: 3 Stocks in Focus - March 19 at 4:42 PM
Cryolife (CRY) & NuVasive (NUVA) Head-To-Head ReviewCryolife (CRY) & NuVasive (NUVA) Head-To-Head Review - March 16 at 12:31 PM
NuVasive, Inc. (NUVA) Expected to Post Quarterly Sales of $260.59 MillionNuVasive, Inc. (NUVA) Expected to Post Quarterly Sales of $260.59 Million - March 14 at 4:58 AM
Financial Survey: NuVasive (NUVA) versus Cryolife (CRY)Financial Survey: NuVasive (NUVA) versus Cryolife (CRY) - March 10 at 5:06 PM
Gregory T. Lucier Purchases 6,000 Shares of NuVasive, Inc. (NUVA) StockGregory T. Lucier Purchases 6,000 Shares of NuVasive, Inc. (NUVA) Stock - March 8 at 6:45 PM
NuVasive Gains From International Business Amid Pricing WoesNuVasive Gains From International Business Amid Pricing Woes - March 7 at 5:41 PM
NuVasive, Inc. (NUVA) is Tamarack Advisers LPs 5th Largest PositionNuVasive, Inc. (NUVA) is Tamarack Advisers LP's 5th Largest Position - March 6 at 10:30 AM
Axa Boosts Holdings in NuVasive, Inc. (NUVA)Axa Boosts Holdings in NuVasive, Inc. (NUVA) - March 6 at 4:46 AM
Insider Buying: NuVasive, Inc. (NUVA) CEO Acquires 6,000 Shares of StockInsider Buying: NuVasive, Inc. (NUVA) CEO Acquires 6,000 Shares of Stock - March 5 at 7:00 PM
NuVasive to Participate in Investor Events in March 2018NuVasive to Participate in Investor Events in March 2018 - March 5 at 5:20 PM
NuVasive, Inc. (NUVA) Expected to Earn FY2018 Earnings of $2.45 Per ShareNuVasive, Inc. (NUVA) Expected to Earn FY2018 Earnings of $2.45 Per Share - March 5 at 5:22 AM
ValuEngine Downgrades NuVasive (NUVA) to SellValuEngine Downgrades NuVasive (NUVA) to Sell - March 4 at 1:58 PM
NuVasive, Inc. (NUVA) Stake Raised by Teacher Retirement System of TexasNuVasive, Inc. (NUVA) Stake Raised by Teacher Retirement System of Texas - March 4 at 7:06 AM
NuVasive (NUVA) Lifted to "Sell" at BidaskClubNuVasive (NUVA) Lifted to "Sell" at BidaskClub - March 3 at 10:34 PM
Broadfin Capital LLC Has $4.80 Million Stake in NuVasive, Inc. (NUVA)Broadfin Capital LLC Has $4.80 Million Stake in NuVasive, Inc. (NUVA) - March 3 at 4:53 AM
Gabelli Brokers Boost Earnings Estimates for NuVasive, Inc. (NUVA)Gabelli Brokers Boost Earnings Estimates for NuVasive, Inc. (NUVA) - March 2 at 4:04 PM
NuVasive, Inc. (NUVA) Shares Bought by Altrinsic Global Advisors LLCNuVasive, Inc. (NUVA) Shares Bought by Altrinsic Global Advisors LLC - March 2 at 4:10 AM
NuVasive, Inc. (NUVA) Position Raised by Swiss National BankNuVasive, Inc. (NUVA) Position Raised by Swiss National Bank - March 1 at 5:42 PM
Q4 2018 EPS Estimates for NuVasive, Inc. Boosted by Analyst (NUVA)Q4 2018 EPS Estimates for NuVasive, Inc. Boosted by Analyst (NUVA) - March 1 at 1:30 PM
NuVasive, Inc. (NUVA) Forecasted to Earn Q1 2018 Earnings of $0.49 Per ShareNuVasive, Inc. (NUVA) Forecasted to Earn Q1 2018 Earnings of $0.49 Per Share - March 1 at 7:30 AM
Q1 2018 EPS Estimates for NuVasive, Inc. (NUVA) Lifted by Leerink SwannQ1 2018 EPS Estimates for NuVasive, Inc. (NUVA) Lifted by Leerink Swann - March 1 at 7:30 AM
Stock Traders Buy High Volume of Put Options on NuVasive (NUVA)Stock Traders Buy High Volume of Put Options on NuVasive (NUVA) - March 1 at 7:24 AM
Leerink Swann Comments on NuVasive, Inc.s Q3 2018 Earnings (NUVA)Leerink Swann Comments on NuVasive, Inc.'s Q3 2018 Earnings (NUVA) - February 28 at 10:32 AM
Q1 2018 EPS Estimates for NuVasive, Inc. (NUVA) Cut by William BlairQ1 2018 EPS Estimates for NuVasive, Inc. (NUVA) Cut by William Blair - February 28 at 8:08 AM
NuVasive (NUVA) Given Hold Rating at Robert W. BairdNuVasive (NUVA) Given Hold Rating at Robert W. Baird - February 27 at 9:34 PM
NuVasive, Inc. (NUVA) Receives Average Recommendation of "Buy" from BrokeragesNuVasive, Inc. (NUVA) Receives Average Recommendation of "Buy" from Brokerages - February 27 at 7:31 PM
Cowen Analysts Give NuVasive (NUVA) a $62.00 Price TargetCowen Analysts Give NuVasive (NUVA) a $62.00 Price Target - February 27 at 7:22 PM
NuVasive (NUVA) Rating Reiterated by BarclaysNuVasive (NUVA) Rating Reiterated by Barclays - February 27 at 6:18 PM
NuVasive (NUVA) Meets Q4 Earnings Estimates, Issues 18 ViewNuVasive (NUVA) Meets Q4 Earnings Estimates, Issues '18 View - February 27 at 5:21 PM
NuVasive (NUVA) Meets Q4 Earnings Estimates, Issues '18 ViewNuVasive (NUVA) Meets Q4 Earnings Estimates, Issues '18 View - February 27 at 5:21 PM
NuVasives (NUVA) "Hold" Rating Reaffirmed at Leerink SwannNuVasive's (NUVA) "Hold" Rating Reaffirmed at Leerink Swann - February 27 at 3:32 PM
NuVasive (NUVA) PT Lowered to $73.00 at Canaccord GenuityNuVasive (NUVA) PT Lowered to $73.00 at Canaccord Genuity - February 27 at 3:30 PM
NuVasive (NUVA) Price Target Cut to $70.00 by Analysts at Needham & Company LLCNuVasive (NUVA) Price Target Cut to $70.00 by Analysts at Needham & Company LLC - February 27 at 1:07 PM
NuVasive (NUVA) PT Lowered to $55.00NuVasive (NUVA) PT Lowered to $55.00 - February 27 at 12:25 PM
NuVasive, Inc. 2017 Q4 - Results - Earnings Call SlidesNuVasive, Inc. 2017 Q4 - Results - Earnings Call Slides - February 27 at 9:04 AM
NuVasive Sees a Stronger 2018NuVasive Sees a Stronger 2018 - February 27 at 9:04 AM
NuVasive (NUVA) Updates FY18 Earnings GuidanceNuVasive (NUVA) Updates FY18 Earnings Guidance - February 26 at 5:46 PM
Whats in the Cards for Genomic Health (GHDX) in Q4 Earnings?What's in the Cards for Genomic Health (GHDX) in Q4 Earnings? - February 26 at 5:14 PM
NuVasive meets 4Q profit forecastsNuVasive meets 4Q profit forecasts - February 26 at 5:14 PM
NuVasive Reports Fourth Quarter and Full Year 2017 Financial ResultsNuVasive Reports Fourth Quarter and Full Year 2017 Financial Results - February 26 at 5:14 PM
NuVasive (NUVA) Issues  Earnings ResultsNuVasive (NUVA) Issues Earnings Results - February 26 at 5:12 PM
OppenheimerFunds Inc. Decreases Holdings in NuVasive, Inc. (NUVA)OppenheimerFunds Inc. Decreases Holdings in NuVasive, Inc. (NUVA) - February 26 at 1:48 PM
Champlain Investment Partners LLC Has $167.65 Million Holdings in NuVasive, Inc. (NUVA)Champlain Investment Partners LLC Has $167.65 Million Holdings in NuVasive, Inc. (NUVA) - February 26 at 1:02 PM
Carillon Tower Advisers Inc. Acquires New Position in NuVasive, Inc. (NUVA)Carillon Tower Advisers Inc. Acquires New Position in NuVasive, Inc. (NUVA) - February 26 at 12:01 PM
State of Wisconsin Investment Board Increases Position in NuVasive, Inc. (NUVA)State of Wisconsin Investment Board Increases Position in NuVasive, Inc. (NUVA) - February 26 at 11:46 AM
Does NuVasive Inc’s (NASDAQ:NUVA) Recent Track Record Look Strong?Does NuVasive Inc’s (NASDAQ:NUVA) Recent Track Record Look Strong? - February 26 at 8:56 AM
Financial Survey: Neurometrix (NURO) vs. NuVasive (NUVA)Financial Survey: Neurometrix (NURO) vs. NuVasive (NUVA) - February 25 at 11:58 AM
NuVasive, Inc. (NUVA) Shares Sold by Sei Investments Co.NuVasive, Inc. (NUVA) Shares Sold by Sei Investments Co. - February 25 at 7:48 AM
$272.29 Million in Sales Expected for NuVasive, Inc. (NUVA) This Quarter$272.29 Million in Sales Expected for NuVasive, Inc. (NUVA) This Quarter - February 25 at 2:02 AM
365,000 Shares in NuVasive, Inc. (NUVA) Acquired by State of Tennessee Treasury Department365,000 Shares in NuVasive, Inc. (NUVA) Acquired by State of Tennessee Treasury Department - February 24 at 2:34 PM

SEC Filings

NuVasive (NASDAQ:NUVA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


NuVasive (NASDAQ:NUVA) Income Statement, Balance Sheet and Cash Flow Statement


NuVasive (NASDAQ NUVA) Stock Chart for Wednesday, March, 21, 2018

Loading chart…

This page was last updated on 3/21/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.